Skip to content
Subscriber Only

Dendreon Wins Final Medicare Ruling on Prostate Cancer Drug

Dendreon Corp.’s prostate cancer medicine Provenge should be covered by the U.S. health plan for the elderly and disabled, regulators said, confirming a proposal from March.

The Centers for Medicare & Medicaid Services issued a final ruling today saying the $93,000 treatment is “reasonable and necessary” for men with advanced, prostate tumors resistant to hormone therapy who have minimal or no symptoms. The decision is in line with prescribing information for the drug approved in April 2010.